Although nab-paclitaxel and gemcitabine are considered to have low emetogenicity, the incidence of nausea and vomiting reported in trials suggest that this regimen is more emetogenic than predicted in models.
Suggested default antiemetics have been added to the treatment schedule, and may be substituted to reflect institutional policy.
Ensure that patients also have sufficient antiemetics for breakthrough emesis:
Metoclopramide 10 mg three times a day when necessary (maximum of 30 mg/24 hours, up to 5 days) OR
Prochlorperazine 10 mg PO or 12.5 mg IV every 6 hours when necessary.